Westfield, NJ, United States of America

Yawei Shi

This inventor holds 2 USPTO granted patents. Top assignee: Forma Therapeutics, Inc.. Active years: 2020-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yawei Shi. Retrieved from https://idiyas.com/inventor/yawei-shi-hdu9aeb1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 50.0

Average Co-Inventor Count = 6.5

ph-index = 1


Company Filing History:


Years Active: 2020-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Yawei Shi

Introduction

Yawei Shi is a notable inventor based in Westfield, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 2 patents. His work focuses on the development of solid forms of complex chemical compounds, which are crucial for various therapeutic applications.

Latest Patents

Yawei Shi's latest patents include innovative formulations of solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazine-1-yl)(1-hydroxycyclopropyl)methanone. These patents detail the solid forms of this compound, which are essential for enhancing the stability and efficacy of the drug.

Career Highlights

Yawei Shi is currently employed at Forma Therapeutics, Inc., where he continues to advance his research and development efforts. His expertise in pharmaceutical formulations has positioned him as a valuable asset in the industry.

Collaborations

Throughout his career, Yawei has collaborated with esteemed colleagues, including George P. Luke and Stephen Hubbs. These partnerships have fostered a collaborative environment that enhances innovation and drives successful outcomes in their projects.

Conclusion

Yawei Shi's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to innovation. His work continues to impact the industry positively, paving the way for future advancements in drug development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…